缩短肝癌筛查间隔对乙型肝炎肝硬化相关肝细胞癌患者预后的影响

李鹏; 丁惠国; 徐辉; 张世斌; 张月宁; 王贞彪; 吴燕京; 于海滨

doi:10.3969/j.issn.1001-5256.2017.07.019

缩短肝癌筛查间隔对乙型肝炎肝硬化相关肝细胞癌患者预后的影响

DOI: 10.3969/j.issn.1001-5256.2017.07.019

首都医科大学附属北京佑安医院消化中心

基金项目:

佑安肝病艾滋病基金(YNKT20160024)；

详细信息

中图分类号: R512.62;R735.7
计量
- 文章访问数: 2478
- HTML全文浏览量: 17
- PDF下载量: 425
- 被引次数: 0
出版历程
- 收稿日期: 2017-01-25
- 出版日期: 2017-07-20

Shortening liver cancer screening interval may improve the prognosis of patients with hepatitis B cirrhosis-related hepatocellular carcinoma

Department of Gastroenterology and Hepatology, Beijing You An Hospital, Capital Medical University

Research funding:

摘要

摘要: 目的探讨缩短肝癌筛查间隔对乙型肝炎肝硬化患者早期肝细胞癌（HCC）检出情况及预后的影响,探索针对这一HCC高危人群的适宜筛查方案。方法收集2007年1月-2008年1月北京佑安医院消化中心诊治的乙型肝炎肝硬化患者310例,按其筛查时间分为间隔3个月筛查组（A组）78例和间隔6个月筛查组（B组）232例。筛查项目为血清AFP及B超,随访5年,对期间检出的HCC患者继续随访至终点（死亡或2016年12月31日）。比较2组患者HCC的检出情况和预后。2组间计量资料比较采用t检验,计数资料比较采用χ2检验或Fisher检验;生存分析采用Kaplan-Meier法。结果 310例患者至随访5年结束累积检出HCC 73例,A组21例,B组52例;A组中巴塞罗那肝癌分期中属于早期（A期）者占66.7%（14/21）,显著高于B组的15.4%（8/52）（χ2=18.685,P<0.001）。A组行根治性治疗的患者比例显著高于B组（76.2%vs 36.5%,χ2=9.424,P=0.002）。对检出的HCC癌患者继续随访至终点时...
- 肝炎病毒,乙型 /
- 肝硬化 /
- 癌,肝细胞 /
- 早期诊断 /
- 预后
Abstract: Objective To investigate the influence of shortening liver cancer screening interval on the detection of early-stage hepatocellular carcinoma (HCC) in patients with hepatitis B cirrhosis and their prognosis, as well as proper screening schemes for such patients at a high risk of HCC.Methods A total of 310 patients with hepatitis B cirrhosis who were diagnosed and treated in Department of Gastroenterology and Hepatology, Beijing You An Hospital, from January 2007 to January 2008 were enrolled, and according to the screening interval, they were divided into 3-month screening group (group A) with 78 patients and 6-month screening group (group B) with 232 patients.The screening items included serum alpha-fetoprotein and ultrasound and the patients were followed up for 5 years.The patients with HCC screened out were followed up to the endpoint (death or December 31, 2016) .The detection of HCC and prognosis were compared between the two groups.The t-test was used for comparison of continuous data between groups, the chi-square test or Fisher's exact test was used for comparison of categorical data between groups, and the Kaplan-Meier method was used for survival analysis.Results At the end of the5-year follow-up, 73 patients were diagnosed with HCC, with 21 in group A and 52 in group B.Group A had a significantly higher proportion of patients with early-stage HCC (Barcelona Clinic Liver Cancer stage A) than group B [66.7% (14/21) vs 15.4% (8/52) , χ2=18.685, P<0.001].Group A also had a significantly higher proportion of patients who underwent radical surgery than group B (76.2% vs 36.5%, χ2=9.424, P=0.002) .The patients with HCC were followed up to the endpoint, and compared with group B, group A had a significantly longer cumulative survival time (66.4 ± 8.0 months vs 38.1 ± 4.5 months, t=4.295, P=0.038) and a significantly higher cumulative survival rate [71.4% (15/21) vs 46.2% (24/52) , χ2=3.840, P=0.043].Conclusion For patients with hepatitis B cirrhosis, a 3-month screening interval can increase the early detection rate of HCC, bring the opportunity of radical treatment for these patients, and prolong their survival time.
- hepatitis B virus /
- liver cirrhosis /
- carcinoma, hepatocellular /
- early diagnosis /
- prognosis

HTML全文

参考文献(20)

[1]QI JH, WANG J, KATAYAMA H, et al.Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma[J].Neoplasma, 2013, 60 (2) :135-142.

[2]VILANA R, FORNER A, GARCIA AN, et al.Hepatocellular carcinoma:diagnosis, staging, and treatment strategy[J].Radiologia, 2010, 52 (5) :385-398.

[3]KUDO M.The 2008 Okuda lecture:management of hepatocellular carcinoma:from surveillance to molecular targeted therapy[J].J Gastroenterol Hepatol, 2010, 25 (3) :439-452.

[4]OMATA M, LESMANA LA, TATEISHI R, et al.Asian Pacific Association for the study of the liver consensus recommendations on hepatocellular carcinoma[J].Hepatol Int, 2010, 4 (2) :439-474.

[5]BRUIX J, SHERMAN M, LLOVET JM, et al.Clinical management of hepatocellular carcinoma.Conclusion of the Barcelona-2000EASL Conference[J].J Hepatol, 2001, 35 (3) :421-430.

[6]BRUIX J, SHERMAN M.Management of hepatocellular carcinoma-an update[J].Hepatology, 2011, 53 (3) :1020-1022.

[7]LI P, CHEN YH, ZHANG SB, et al.Comparison of dierent hepatocarcinoma screening schemes for patients with hepatitis B associated cirrhosis:Detection rate and impact on prognosis[J].World Chin JDig, 2015, 20 (23) :3298-3303. (in Chinese) 李鹏, 陈玉涵, 张世斌, 等.乙型肝炎肝硬化患者不同肝癌筛查方案的比较及对预后影响[J].世界华人消化杂志, 2015, 20 (23) :3298-3303.

[8] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :I-XVI. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :I-XVI.

[9]Ministry of Health of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma[J].J Clin Hepatol, 2011, 27 (11) :1141-1159. (in Chinese) 中华人民共和国卫生部, 原发性肝癌诊疗规则 (2011年版) [J].临床肝胆病杂志, 2011, 27 (11) :1141-1159.

[10]FORNER A, REIG ME, de l OPE CR, et al.Current strategy for staging and treatment:the BCLC update and future prospects[J].Semin Liver Dis, 2010, 30 (1) :61-74.

[11]LIN SM, LIN CJ, LIN CC, et al.Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3cm or less[J].Gut, 2005, 54 (8) :1151-1156.

[12]WANG JH, CHANGCHIEN CS, HU TH, et al.The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma-survival analysis of 3892 patients[J].Eur JCancer, 2008, 44 (7) :1000-1006.

[13]TSENG PL, WANG JH, TUNG HD, et al.Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening[J].J Gastroenterol Hepatol, 2010, 25 (8) :1426-1434.

[14]KUO YH, LU SN, CHEN CL, et al.Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis[J].Eur J Cancer, 2010, 46 (4) :744-751.

[15]LLOVET JM, DUCREUX M, LENCIONI R.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma[J].JHepatol, 2012, 56 (4) :908-943.

[16]STEFANIUK P, CIANCIARA J, WIERCINSKA-DRAPALO A.Present and future possibilities for early diagnosis of hepatocellular carcinoma[J].World J Gastroenterol, 2010, 16 (4) :418-424.

[17]LIN H, ZHENG WD.The diagnosis and prognostic value of AFP, AFU, TSGF and IL-8 in liver transplantation patients with liver cancer[J].J Clin Exp Med, 2017, 16 (8) :776-780. (in Chinese) 林花, 郑卫东.AFP、AFU、TSGF及IL-8对肝癌患者诊断及肝移植术预后评估的价值研究[J].临床和实验医学杂志, 2017, 16 (8) :776-780.

[18]ZHU QX.Diagnostic value of joint detection of golgin 73, alphafetoprotein, alpha-fetoprotein variants for primary hepatocellular carcinoma[J].China Med Herald, 2016, 13 (5) :130-133. (in Chinese) 诸琴红.高尔基体蛋白73、甲胎蛋白、甲胎蛋白异质体3%联合检测对原发性肝癌的诊断价值[J].中国医药导报, 2016, 13 (5) :130-133.

[19]LI JL, SHAGN J, NING HB, et al.Role of serum abnormal prothrombin protein induced by vitamin K absence or antagonist-II in development and progression of hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (1) :171-174. (in Chinese) 李俊利, 尚佳, 宁会彬, 等.PIVKA-II在肝细胞癌诊断及预后判断中的作用[J].临床肝胆病杂志, 2017, 33 (1) :171-174.

[20]KOKUDO N, HASEGAWA K, AKAHANE M, et al.Evidence-based clinical practice guidelines for hepatocellular carcinoma:the Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines) [J].Hepatol Res, 2015, 45 (2) :123-127.

施引文献

资源附件(0)

访问统计